United-Guardian, Inc. (UG) is a publicly traded Consumer Defensive sector company. As of May 21, 2026, UG trades at $7.02 with a market cap of $32.21M and a P/E ratio of 13.51. UG moved -0.56% today. Year to date, UG is +14.85%; over the trailing twelve months it is -18.38%. Its 52-week range spans $5.58 to $16.00. Rallies surfaces UG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in UG news today?
United-Guardian Q1 Sales Up 16% to $2.87M, Earnings Rise 46%: United-Guardian’s Q1 sales rose 15.7% to $2,872,222 while net income jumped 46% to $818,902 ($0.18 per share). Pharmaceutical revenue grew 24% on higher Renacidin demand, cosmetic ingredient sales climbed 21% with Ashland Specialty Ingredients boosting orders by 45%, and a $303,133 settlement added to income.
VERNICE JOSEPH J sold 3.13K (~$46.74K) on Aug 15, 2016.
VERNICE JOSEPH J bought 1.40K (~$20.66K) on Aug 15, 2016.
Parker Betsee sold 500 (~$9.25K) on Sep 22, 2015.
UG Analyst Consensus
UG analyst coverage data. Average price target: $0.00.
Common questions about UG
What changed in UG news today?
United-Guardian Q1 Sales Up 16% to $2.87M, Earnings Rise 46%: United-Guardian’s Q1 sales rose 15.7% to $2,872,222 while net income jumped 46% to $818,902 ($0.18 per share). Pharmaceutical revenue grew 24% on higher Renacidin demand, cosmetic ingredient sales climbed 21% with Ashland Specialty Ingredients boosting orders by 45%, and a $303,133 settlement added to income.
Does Rallies summarize UG news?
Yes. Rallies summarizes UG news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is UG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for UG. It does not provide personalized investment advice.
